Myeloma Trial, Recruiting NCT07052916 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT07052916
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older who are proficient in English
  • People who have been diagnosed with lymphoma, leukemia, or myeloma
  • People whose cancer is stable or shows no signs of active disease, as confirmed by their medical records or oncology team
  • People who score below 54 on a specific memory and thinking self-assessment tool called the FACT-Cog PCI subscale (confirm with trial site)
  • People whose doctor estimates they have a life expectancy of at least one year
  • People who are able to complete all study assessments independently, without assistance
  • People who are able to understand and sign an informed consent form written in English

Who may not be able to join:

  • People who finished surgery, radiation, induction chemotherapy, transplantation, or certain immunotherapy treatments (such as CAR T-Cell or bispecific antibodies) less than 3 months ago — or, for ongoing continuous therapies, people who have been on that therapy for less than 6 months (note: maintenance therapies are generally allowed)
  • People who have received music therapy in the past year
  • People who are currently receiving music training, have had more than 6 months of music training in the past 10 years, or plan to start music training during the study
  • People who do not have access to a device connected to the internet
  • People who are currently experiencing active suicidal thoughts, or who have a diagnosis of bipolar disorder, schizophrenia, or a substance use disorder
  • People who score 10 or higher on a cognitive screening tool that may indicate dementia (confirm with trial site)
  • People who have vision, hearing, or movement difficulties that cannot be corrected
  • People who have started or changed the dose of certain medications — such as sedatives, stimulants, or anti-cholinergic drugs — in the past month, or who plan to do so during the study, as these are known to affect thinking and memory
  • People who have started any other treatment aimed at improving cancer-related thinking or memory difficulties in the past month, or who plan to do so during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kevin Liou, MD, Memorial Sloan Kettering Cancer Center

Phone: 646-608-8563

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
27 June 2025
Est. completion
27 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Feasibility of studying a telehealth-based Music Therapy/MT intervention for cancer-related cognitive dysfunction/CRCD in hematologic cancer survivors as defined as the completion of 9 or more sessions.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov